GIP has been shown to decrease food intake & increase energy expenditure therefore resulting in weight reductions & when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose, & lipides
Small-molecule inhibitor characterisation
Structurally, BPC-157 is notable for its apparent stability in gastric acid, a characteristic that has made it a subject of interest in gut-related research models, and one that distinguishes it from many peptides that degrade quickly outside controlled conditions
Variants in GLP1R, GIPR, FTO, and MC4R relate to metabolic response
BPC 157 10mg The KLOW BPC 157 component contributes 10mg of synthetic BPC 157 peptide to the composition
Enhancing physical performance is another purpose for it